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Histiocytoid Sweet syndrome (SS) is a rare inﬂammatory disease that has recently been described as
a variant of classic SS. Histopathologically, histiocytoid SS is characterized by papillary dermal edema
with inﬁltration of histiocyte-like cells into the upper dermis. These microscopic features may be similar
to those of leukemia cutis, which involves inﬁltration of malignant blasts into the dermis. However, the
treatment and clinical prognosis of these two conditions are quite different. Here, we report the case of
two Taiwanese patients with histiocytoid SS. Interestingly, one of the patients had a history of myelo-
dysplastic syndrome and was initially considered to have ongoing leukemic transformation with
concomitant leukemia cutis. Finally, the patient was diagnosed with histiocytoid SS based on histological
ﬁndings, and both patients were successfully treated with low-dose oral corticosteroids.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Histiocytoid Sweet syndrome (SS) was ﬁrst described by Requena
et al in 2005 andwas considered to be a histological variant of acute
febrile neutrophilic dermatosis.1 In contrast to classic SS, the
dermal inﬁltrate of inﬂammatory cells in histiocytoid SS consists of
histiocytoid cells, which are considered to be immature myeloid
cells. Here, we report the case of two Taiwanese patients with
histiocytoid SS and review the relevant literature.
Case presentations
Patient 1
A 49-year-old Taiwanese male presented in 2008 with recurrent
tender skin rashes on his chest and abdomen; the lesions sponta-
neously resolved without any treatment. One year later, he expe-
rienced painful swelling of the foot joints bilaterally and came to
our hospital for evaluation. Peripheral blood tests showed a leuko-
cyte count of 6.58 (normal 4.5e11)  109/L, a hemoglobin level of
99 (normal 135e180) g/L, and a platelet count of 23 (normal
150e400)  109/L. Owing to persistent macrocytic anemia and
profound thrombocytopenia, the patient underwent bone marrow, Section 2, Chenggong Road,
6 2 8792 7180; fax: þ886 2
. Chiang).
iwanese Dermatological Associatioexamination and ﬁnally was diagnosed with unclassiﬁed myelo-
dysplastic syndrome (MDS).
Six months later, the same rashes recurred, and the patient was
referred to our dermatological department as the hematologist
suspected that the MDS had transformed to a leukemic state with
leukemia cutis. On physical examination, tender erythematous
papules were found to be diffusely scattered over the chest,
abdomen, back, and upper limbs (Figure 1A and, 1B). In addition,
fever and leukopenia (3.24  109/L) were noted.
Skin biopsy from a papule revealed a dense cellular inﬁltrate
beneath the papillary dermal edema and mild perivascular inﬁl-
tration (Figure 2A). Cells were composed of many seemingly
atypical mononuclear cells, which contained large, reniform nuclei
with scanty eosinophilic cytoplasm (Figure 2A; inset). Additionally,
sparse polymorphonuclear cells, histiocytes, and CD4-positive
reactive lymphocytes were scattered in the dermis. The atypical
mononuclear cells were strongly positive for lysozyme (Figure 2B),
myeloperoxidase (MPO) (Figure 2C), and CD68 (KP1) (Figure 2D).
Staining with CD2, CD15, CD34, CD56 and CD117 for blasts showed
negative results. Chest and abdominal computed tomography
revealed that the patient’s lymph nodes and visceral organs such as
the liver and spleen were normal. Except for the physiological
uptake, positron emission tomography did not show any abnormal
uptake. No myeloid blasts were observed by cytological examina-
tion of peripheral blood and bone marrow.
Finally, based on these ﬁndings, histiocytoid SS was diagnosed.
The lesions resolved gradually over a 14-day tapered-dose course of
oral prednisolone. The patient was regularly followed up in ourn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Patient 1: (A,B) tender erythematous edematous papules on the neck, chest, abdomen, and upper extremities. Patient 2: (C) multiple swelling erythematous
papulonodules on the right forearm; (D) some of the lesions give rise to “an illusion of vesiculation.”
C.-F. Huang et al. / Dermatologica Sinica 30 (2012) 71e7472outpatient department for 15 months. Throughout the follow-up
period, the skin lesions showed improvement and recurred less
frequently under low-dose prednisolone treatment (5 mg/day)
when required.Figure 2 Biopsy specimen from patient 1. (A) Papillary dermal edema with band-like, diffus
mononuclear histiocytoid cells with twisted nuclei and scant cytoplasm (hematoxylin and
Strong immunoexpression for myeloperoxidase (myeloperoxidase stain, 200). (D) PositivePatient 2
A 55-year-old Taiwanese female with an unremarkable medical
history presented with fever as well as tender and mildly pruritice inﬂammation involving the superﬁcial dermis (hematoxylin and eosin, 100); inset:
eosin, 400). (B) Strong immunoreactivity for lysozyme (lysozyme stain, 200). (C)
immunostaining for CD68 (KP1; 200).
C.-F. Huang et al. / Dermatologica Sinica 30 (2012) 71e74 73erythematous to violaceous papulonodules on the abdomen and all
four limbs, which had persisted for about 1 week (Figure 1C). Some
lesions had a transparent, vesicle-like appearance, giving rise to “an
illusion of vesiculation” (Figure 1D). Laboratory examination
revealed peripheral neutrophiliawithout blasts in the blood, and an
elevated erythrocyte sedimentation rate and C-reactive protein
level. Histopathological analysis showed tense papillary dermal
edema with inﬁltration of histiocytoid cells (Figure 3A). Immuno-
histochemical assessment revealed the same results as those
observed in Patient 1 (Figure 3BeD). The physical examination did
not show palpable lymph nodes. The chest X-ray and abdominal
sonography showed no signs of hilar lymphadenopathy and hep-
atosplenomegaly. Based on these ﬁndings, the patient was diag-
nosed with histiocytoid SS. The cutaneous lesions subsided with
systemic administration of methylprednisolone 40 mg/day for 1
week. At the 12-month follow-up after cessation of oral cortico-
steroids, the patient was still free of cutaneous lesions.
Discussion
SS is a well-recognized inﬂammatory dermatosis characterized by
dermal inﬁltration of polymorphonuclear leukocytes. In the present
two cases, the clinical picture of both patients was consistent with
SS. However, microscopic ﬁndings in both patients differed from
those of typical SS as the dermal inﬁltrate was composed of mono-
nuclear cells with histiocytoid morphology. In addition, leukopenia
was seen in one of our patients, which has been shown rarely to
occur in combination with histiocytoid SS.2 Both our patients were
regularly followed up in our outpatient department for more than 1
year after the diagnosis of histiocytoid SS; the general condition of
both patients was good throughout follow-up, without evidence of
leukemic transformation or other visceral malignancy.
In 2005, Requena et al ﬁrst described a series of 41 patients with
SS with dermal inﬁltration of histiocytoid cells, which manifestedFigure 3 Biopsy specimen from patient 2. (A) Inﬂammatory cellular inﬁltrate with severe
composed of histiocyte-like cells (hematoxylin and eosin, 400). (B) Strong immunoreactiv
oxidase (myeloperoxidase stain, 200). (D) Positive immunostaining for CD68 (KP1; 200)as large, twisted, basophilic vesicular nuclei with scant eosinophilic
cytoplasm.1 In addition, immunostaining results of histiocyte-like
cells were found to be strongly positive for CD68 (KP1), lysozyme,
and MPO. The CD68 stain tests for both KP1 and PGM1. KP1 is
positive in cells of both myeloid and monocytic/histiocytic lineage;
however, PGM1 is more selective for monocytes/histiocytes. In
histiocytoid SS, immature cells are strongly stained with KP1.1
Other speciﬁc indicators for discriminating cells of myeloid
lineage include neutrophil elastase, T-cell intracellular antigen-1,
and MPO. Nevertheless, the most reliable marker for distinguish-
ing myeloid cells from monocytes/histiocytes is MPO, which is the
major component of primary granules in myeloid cells, including
early andmature forms. Requena et al considered that the observed
cells with histiocytic appearancewere immaturemyeloid cells from
the bonemarrow in the early acute stage, and therefore deﬁned the
described condition as a histiocytoid variant of SS.
The signiﬁcance of histiocytoid SS is its association with other
medical conditions such as diabetes mellitus and internal malig-
nancy. In the report of 41 patients, six cases of histiocytoid SS were
associated with malignant neoplasms and four with hematological
malignancies.1
Although the mechanism of migration of immature myeloid
cells to the skin is well documented in myelogenous leukemia,3 the
pathogenesis of histiocytoid SS is still not clear. Granulocyte colony-
stimulating factor is known to promote the maturation of myeloid
cells, and recent studies have shown that this factor may play an
important role in the pathogenesis of SS.4 However, the levels of
granulocyte-colony stimulating factor observed in histiocytoid SS
may be too low to stimulate neutrophil maturation.1 In addition,
CXCL8-producing T-cells, which may secrete granulocyte/macro-
phage colony-stimulating factor and interleukin-8 to attract
immature granulocytes, may also inﬂuence neutrophilic skin
inﬂammation.5 These possible underlying mechanisms need to be
assessed in further studies.papillary dermal edema (hematoxylin and eosin, 100); inset: inﬂammatory inﬁltrate
ity for lysozyme (lysozyme stain, 200). (C) Strong immunoexpression for myeloper-
.
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Murase et al described the case of a 69-year-old manwith multiple
myeloma treatedwith bortezomib, who developed histiocytoid SS.6
In addition, Wu et al reported the case of a patient with sinusitis
treated with trimethoprim-sulfamethoxasole(TMP-SMX), who
subsequently developed severe leukopenia with histiocytoid SS;
the authors proposed that TMP-SMX may have arrested idiosyn-
cratic granulocytic maturation, thereby inducing histiocytoid SS.7
Generally, histiocytoid SS needs to be differentiated from several
cutaneous dermatoses characterized by the inﬁltration of abundant
histiocytes, including interstitial granuloma annulare and intersti-
tial granulomatous dermatitis with arthritis.8 More importantly, in
patients with MDS, leukemia cutis always should be considered
before establishing the diagnosis of SS. Leukemia cutis is clinically
identiﬁable by the inﬁltration of neoplastic leukocytes (immature
myeloid or lymphoid cells) into the skin. In MDS patients, leukemic
transformation to myeloid leukemia has previously been reported,
and leukemia cutis may be observed before, concomitant with, or
after this leukemic change.
Clinically, myeloid leukemia cutis presents as erythematous or
violaceous papuloplaques and nodules on the face, trunk, or
extremities.9 On histological examination, diffuse inﬁltration of
malignant blasts with prominent nuclei is observed beneath an
uninvolved grenz zone, which may involve periadnexal, peri-
vascular, and/or perineural areas.10 Most cells reveal positive
immunohistochemicalﬁndings for CD68 (KP1), lysozyme, andMPO.
In addition, peripheral blood examination or bone marrow aspira-
tionwill also show leukemic cells, and patients with leukemia cutis
usually have anunfavorable disease course. However, in histiocytoid
SS, leukemic cells are absent in peripheral blood tests, as well as in
thebonemarrow, and the lesions resolvedramaticallywith systemic
corticosteroid use, as is the case in classic SS.
Spencer et al reported the case of a patient with histiocytoid SS
associated with Crohn’s disease who responded well to dapsone
therapy.11 Both of our patients were successfully treated with
systemic corticosteroid administration; however, the ﬁrst patient,
who had underlying MDS, experienced recurrent eruptions after
cessation of oral prednisolone. Hence, therapy focusing on theunderlying disease in patients with histiocytoid SS associated with
malignancy may prevent recurrent cutaneous lesions. Recently,
a case of histiocytoid SS associated with MDS was reportedly
successfully treated by allogeneic stem cell transplantation, which
may be the treatment of choice for histiocytoid SS accompanied
with hematologic malignancy.12
In conclusion, we have reported two cases of histiocytoid SS that
were diagnosed histologically. Because the prognosis and biological
behavior of histiocytoid SS does not differ from that of classic SS,8
we propose that classic SS and histiocytoid SS may be part of
a spectrum of the same disease. The diagnosis of histiocytoid SS
should be a diagnosis of exclusion, and clinicopathological corre-
lation is essential.
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